

Healthcare utilization and costs by disease stage in beneficiaries with Huntington's disease in the US Medicare population



Genentech
A Member of the Roche Group

Alex Exuzides,¹ Valerie Crowell,² Sheila Reiss Reddy,³ Eunice Chang,³ George Yohrling⁴

(1) Genentech Inc, South San Francisco, CA, USA; (2) Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; (3) Partnership for Health Analytic Research (PHAR), LLC, Beverly Hills, CA, USA; (4) Huntington's Disease Society of America (HDSA), New York, NY, USA.

What does this study mean for the HD community?

The total healthcare resource utilisation (HCU) and costs for individuals with late-stage Huntington's disease (HD) were significantly higher than those with early- or middle-stage HD, highlighting the considerable economic burden late-stage disease exerts on the US healthcare service. Development of an effective disease-modifying treatment of HD could potentially reduce these substantial costs in the long-term.

Conclusions

- Medicare beneficiaries with HD have significant HCU and cost burden.
- Over 50% of individuals with HD identified in the Medicare population had late-stage disease.
- Late-stage HD Medicare beneficiaries have a significantly higher HCU and cost burden compared with beneficiaries with early- and middle-stage HD.

BACKGROUND



- HD is a rare, genetic, neurodegenerative and ultimately fatal disease that has a devastating impact on families across generations.^{1,2}
- Quantifying the direct healthcare costs and resource utilisation associated with HD in individuals with early-, middle- and late-stage disease will provide a valuable insight into the economic impact of this disease through the various stages of its progression.



Objective: Investigate the healthcare utilisation and cost burden by stage of disease progression among US Medicare beneficiaries with HD.

METHODS



- A retrospective study was conducted using the 2013–2017 Medicare Research Identifiable Files (100%).
- Beneficiaries with HD were identified based on having ≥ 1 medical claim with a diagnosis code for HD (International Classification of Diseases [ICD]-9-Clinical Modification [CM]: 333.4; ICD-10-CM: G10) during the identification period (2014–2016).
- Date of HD claim was defined as the index date.


- For multiple HD claims, one was randomly chosen as the index to capture all disease stages.
- Included beneficiaries had continuous enrolment in fee-for-service Medicare one year prior to (baseline) and one year after (follow-up) index.
- Demographics and chronic conditions³ were measured during baseline; healthcare utilisation and costs during follow-up.
- Measures were stratified by early-, middle- and late-stage disease, determined by evidence in claims of diagnoses and services received one year after index.⁴



Study demographics

- 3,688 beneficiaries with HD were identified, of which 1,922 (52.1%) had late-stage disease (Figure 1).
- Mean age, sex and number of chronic comorbid conditions varied by disease stage (Table 1).

Figure 1. Percentage of HD beneficiaries by stage




* Based on the claims occurring in the one year post-index.

Table 1. Demographics of HD beneficiaries

HD stage	Age, years (SD)	Female, %	Chronic conditions, mean (SD)
Early (n=850)	64.6 (12.2)	48.8	4.3 (2.4)
Middle (n=916)	69.3 (11.5)	57.0	5.5 (2.4)
Late (n=1,922)	68.5 (12.7)	54.1	6.0 (2.6)
Total (N=3,688)	67.8 (12.4)	53.6	5.4 (2.6)


RESULTS



Annual healthcare costs

- Total annual healthcare costs were highest among beneficiaries with late-stage HD ($p < 0.001$) (Figure 2).

Figure 2. Mean total healthcare costs by stage*




* All pair-wise differences among stages were statistically significant ($p < 0.001$).



Annual healthcare resource utilisation by stage


- A greater percentage of late-stage HD beneficiaries were on medication (Figure 3), visited the emergency department and were hospitalised (Figure 4); all $p < 0.001$.

Figure 3. Medication use*



* All pair-wise differences in medication use among stages were statistically significant ($p < 0.05$).

Figure 4. Hospitalisations and emergency department visits*



* All pair-wise differences in hospitalisations and emergency department visits among stages were statistically significant ($p < 0.001$).

Acknowledgements

We thank all the patients who participate in our studies and their families. This study is funded by F. Hoffmann-La Roche Ltd. The authors thank Greg Rowe, of Meditech Media UK for providing editorial support for this poster, which was funded by F. Hoffmann-La Roche Ltd in accordance with Good Publication Practice (GPP3) guidelines (<http://www.ismpp.org/gpp3>).

Abbreviations

CM, Clinical Modification; HCU, healthcare resource utilisation; HD, Huntington's disease; ICD, International Classification of Diseases; SD, standard deviation.

References

1. Bates GP et al. *Nat Rev Dis Primers*. 2015; 1:15005; 2. Roos RA. *Orphanet J Rare Dis*. 2010; 20:40–48; 3. Agency for Healthcare Research and Quality. HCU Chronic Condition Indicator. Healthcare Cost and Utilization Project (HCUP). 2015. Available from: www.hcup-us.ahrq.gov/toolssoftware/chronic/chronic.jsp. Accessed May 2020; 4. Divino V, et al. *J Med Econ*. 2013; 16:1043–1050.



Please scan using your QR reader application to access this poster on your mobile device. NB: there may be associated costs for downloading data. These costs may be high if you are using your smartphone abroad.

Please check your mobile data tariff or contact your service provider for more details. Alternatively this can be accessed at: <https://bit.ly/2XkvZQT>